LOS ANGELES--(BUSINESS WIRE)--Glancy Prongay & Murray LLP, a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of Sanara MedTech Inc. ("Sanara†or the "Company†) (NASDAQ: SMTI) investors concerning the Company's possible violations of the federal securities laws. IF YOU ARE AN INVESTOR WHO LOST MONEY ON SANARA MEDTECH INC. (SMTI), CLICK HERE TO INQUIRE ABOUT POTENTIALLY PURSUING CLAIMS TO RECOVER YOUR LOSS. What Happened? On Novem. ...

LOS ANGELES--(BUSINESS WIRE)--The Law Offices of Frank R. Cruz announces an investigation of Sanara MedTech Inc. ("Sanara†or the "Company†) (NASDAQ: SMTI) on behalf of investors concerning the Company's possible violations of federal securities laws. IF YOU ARE AN INVESTOR WHO LOST MONEY ON SANARA MEDTECH INC. (SMTI), CLICK HERE TO INQUIRE ABOUT POTENTIALLY PURSUING A CLAIM TO RECOVER YOUR LOSS. What Is the Investigation About? On November 11, 2025, after market hours, Sanara announced that it. ...

FORT WORTH, TX, Nov. 19, 2025 (GLOBE NEWSWIRE) -- Sanara MedTech Inc. (“Sanara,” the “Company,” “we,” “our” or “us”) (Nasdaq: SMTI), a medical technology company focused on developing and commercializing transformative technologies to improve clinical outcomes and reduce healthcare expenditures in the surgical market, announced today that management will participate in the Piper Sandler 37th Annual Healthcare Conference, which is being held at The Lotte New York Palace in New York, NY from December 2 – 4, 2 ...

Sanara MedTech Inc. (NASDAQ:SMTI) reported a significant miss in earnings per share (EPS) at -$3.40, against the estimated -$0.24.Despite a 22% revenue growth year-over-year, reaching $26.3 million, SMTI fell short of the expected $29.9 million.The company's financial metrics reveal challenges, including a negative price-to-earnings (P/E) ratio of approximately -18.30 and a high enterprise value to operating cash flow ratio of approximately 59.33.Sanara MedTech Inc. (NASDAQ: SMTI) is a company focused on me ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ________ to ________ Commission File Number 001-39678 SANARA MEDTECH INC. (Exact name of Registrant as specified in its charter) Texas 59-2219994 (State or other jurisdict ...

Core Insights - Sanara MedTech Inc. reported quarterly earnings of $0.09 per share, exceeding the Zacks Consensus Estimate of a loss of $0.24 per share, and showing improvement from a loss of $0.34 per share a year ago, resulting in an earnings surprise of +137.50% [1] - The company posted revenues of $26.33 million for the quarter ended September 2025, which was slightly below the Zacks Consensus Estimate by 1.19%, but an increase from $21.67 million in the same quarter last year [2] - Sanara MedTech has surpassed consensus EPS estimates three times over the last four quarters, indicating a positive trend in earnings performance [2] Future Outlook - The sustainability of the stock's price movement will largely depend on management's commentary during the earnings call and the company's earnings outlook for upcoming quarters [3][4] - The current consensus EPS estimate for the next quarter is -$0.19 on revenues of $31.45 million, and for the current fiscal year, it is -$0.98 on revenues of $107.37 million [7] - The estimate revisions trend for Sanara MedTech was mixed ahead of the earnings release, resulting in a Zacks Rank 3 (Hold), suggesting the stock is expected to perform in line with the market in the near future [6] Industry Context - The Medical - Products industry, to which Sanara MedTech belongs, is currently ranked in the bottom 33% of over 250 Zacks industries, which may impact the stock's performance [8] - Empirical research indicates a strong correlation between near-term stock movements and trends in earnings estimate revisions, which investors can track to gauge potential stock performance [5]

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh. ...

Financial Data and Key Metrics Changes - In Q3 2025, the company achieved net revenue of $26.3 million, representing a 22% year-over-year growth, primarily driven by sales of soft tissue repair products [11][12] - Gross profit increased by $4.8 million, or 24%, to $24.5 million, with gross margin rising approximately 200 basis points to 93% of net revenue [21][22] - Net income from continuing operations was $800,000, or $0.09 per diluted share, compared to a net loss of $200,000, or $0.02 per diluted share in the previous year [23] Business Line Data and Key Metrics Changes - Sales of soft tissue repair products increased by 24% year-over-year to $23.4 million, significantly contributing to overall revenue growth [11][12] - The company expanded its network of independent distributors from over 300 to more than 400 in the last 12 months, enhancing its market reach [13][14] Market Data and Key Metrics Changes - The company sold products into more than 1,400 healthcare facilities over the last 12 months, up from over 1,200 in the prior year, indicating a significant expansion in customer base [14] - The products are approved or contracted for sale in over 4,000 facilities, suggesting substantial future growth potential [15] Company Strategy and Development Direction - The company announced the discontinuation of the Tissue Health Plus (THP) segment to focus resources on its core surgical business, aiming to enhance operational efficiency and long-term growth [9][10][11] - The strategic realignment is intended to capitalize on strengths in the surgical market and improve clinical outcomes while reducing healthcare expenditures [11][27] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's ability to achieve strong revenue growth and profitability, emphasizing the effectiveness of their commercial strategy and the potential for further market penetration [26][27] - The company anticipates total cash investment related to THP will range from $5.5 million to $6.5 million in the second half of 2025, with no material cash spend expected after 2025 [10][25] Other Important Information - The company has made progress in expanding its portfolio of clinical evidence, with two studies published in peer-reviewed journals highlighting the efficacy of CellerateRX Surgical in complex surgical procedures [16][17] - The partnership with Biomimetic Innovations Limited for the OSTIC product is progressing well, with expectations for a U.S. commercial launch in Q1 2027 [18][19] Q&A Session Summary Question: Can you elaborate on initiatives to drive further penetration within existing facilities? - Management highlighted efforts to expand into new specialties and the importance of scientific and clinical evidence in supporting product value [28][29] Question: Should we expect cash savings outside of THP and leverage on sales and marketing? - Management indicated that the current model is working well, with flat headcount and evidence of operating leverage on the EBITDA line [30][31] Question: What are the expectations for growth and margins going forward? - Management expressed confidence in strong performance for the upcoming quarter, despite a significant growth quarter in the previous year [32][33] Question: Why was a strategic partner not considered earlier for THP? - Management explained that the pursuit of a strategic partner began in early 2024, but ultimately did not yield results, leading to the decision to discontinue THP [34][35] Question: What is the trend of total operating expenses following the discontinuation of THP? - Management refrained from providing forward-looking guidance but suggested that historical data could help model future trends [36]

Core Insights - Sanara MedTech Inc. reported a strong financial performance for Q3 2025, with net revenue growth of 22% year-over-year, driven primarily by a 24% increase in sales of surgical soft tissue products [3][6][10]. Financial Summary - Q3 2025 net revenue was $26.3 million, compared to $21.7 million in Q3 2024, marking an increase of $4.7 million [6][10]. - For the first nine months of 2025, net revenue reached $75.6 million, up 25% from $60.4 million in the same period of 2024 [10][16]. - Gross profit for Q3 2025 was $24.5 million, a 24% increase from $19.7 million in Q3 2024, with a gross margin of 93% [7][10]. - Operating income for Q3 2025 was $2.9 million, compared to $0.8 million in Q3 2024, reflecting a 278% increase [9][10]. Operational Developments - The company has ceased operations of its THP segment as part of a strategic realignment to enhance operational efficiency and focus on its core surgical business [3][5][10]. - The strategic realignment is expected to support sustained long-term growth and value creation [3][10]. Profitability Metrics - Net income from continuing operations for Q3 2025 was $0.8 million, compared to a net loss of $0.2 million in Q3 2024 [10][12]. - Adjusted EBITDA for Q3 2025 was $4.9 million, up from $2.6 million in Q3 2024, indicating improved profitability [10][13]. Cash Flow and Debt - As of September 30, 2025, the company had $14.9 million in cash and $45.1 million in long-term debt, compared to $15.9 million and $30.7 million, respectively, at the end of 2024 [14][10]. - Net cash provided by operating activities in Q3 2025 was $2.2 million, slightly up from $2.1 million in Q3 2024 [13][10].

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 11, 2025 SANARA MEDTECH INC. (Exact name of registrant as specified in its charter) (State or other jurisdiction of (Commission (IRS Employer incorporation) File Number) Identification No.) Texas 001-39678 59-2219994 1200 Summit Avenue, Suite 414 Fort Worth, Texas 76102 CURRENT REPORT (Address of pri ...